| Trial Identifier: | 208850 |
| Sponsor: | GlaxoSmithKline |
| Start Date: | March 2019 |
| Primary Completion Date: | April 2024 |
| Study Completion Date: | March 2026 |
| Condition: | Cancer - Other |
For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.
| Language | Description |
| Country | Location |
|---|---|
| Australia, VIC | Melbourne, VIC, Australia, 3000 |
| Canada, ON | Toronto, ON, Canada, M5G 1Z9 |
| France | Bordeaux, France, 33076 |
| France | Villejuif cedex, France, 94805 |
| Japan | Tokyo, Japan, 135-8550 |
| Japan | Tokyo, Japan, 104-0045 |
| Netherlands | AMSTERDAM, Netherlands, 1081 HV |
| Netherlands | AMSTERDAM, Netherlands, 1066 CX |
| South Korea | SEOUL, South Korea, 03080 |
| Spain | Barcelona, Spain, 08035 |
| Spain | Madrid, Spain, 28040 |
| Spain | Madrid, Spain, 28050 |
| United States, TX | Houston, TX, United States, 77030 |
Powered by
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.
Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company